Stocks · News reference

BioCardia Says FDA Finalized Pre-Submission Meeting Minutes For Helix Transendocardial Delivery Catheter; Plans Follow-On Pre-Submission This Quarter Toward Potential De Novo Approval

Aug 24, 2026, 12:31 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 23, 2026, 1:17 PMBenzinga Newsdesk
BioCardia Advancing Towards Shonin Pre-Market Regulatory Submission To Japan's Pharmaceutical And Medical Device Agency In Q4; Plans To File Follow-On De Novo Pre-Submission For Helix Transendocardial Delivery Catheter System
BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update on near term milestones.BioCardia is working
BCDA
SEC EDGARSep 23, 2026, 1:15 PMSEC EDGAR
8-K filing — BioCardia, Inc. (BCDA)
Filed: 2026-09-23 AccNo: 0001437749-26-031011 Size: 172 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
BCDA
BenzingaSep 22, 2026, 5:35 AMTanya Rawat
BioCardia Shares Fall 10% After Hours: Here's Why
BioCardia shares fall 10% after hours after Nasdaq confirms the company regained listing compliance.
BCDA